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Most of pancreatic masses are represented by 
neoplastic processes, primarily ductal adenocarcinoma 
and less frequently neuroendocrine tumor, lymphoma 
and metastasis. On the contrary, non-neoplastic lesions 
are represented by chronic, autoimmune pancreatitis and 
cysts [1, 2]. Pancreatic cancer is the fourth and fifth most 
common cancer in men and women, respectively [3]. Due 
to local invasion or distant metastasis, only 15–20% of 
patients are surgical candidates at presentation. Among 
them, the five-year survival rate is only 10–15% [4]. About 
70% of pancreatic cancers develop in the head while 10–
20% in the body and tail [5]. In many cases, pancreatic 
cancer is diagnosed in the advanced stage of the disease 
and at this point the tumor cannot be surgically excised. 
In fact, at the moment of diagnosis, 52% patients show 
distant disease and 26% have regional spread [6]. 
Endoscopic ultrasound-guided fine-needle aspiration 
(EUS-FNA) is a rapid, safe, cost-effective and accurate 
technique to evaluate and stage pancreatic tumors [7]. 
In addition, this technique has proved a very useful in 
discriminating between suspicious lesions, inflammation 
and cancer, especially adenocarcinomas. The EUS-FNA 
demonstrates a low percentage of major complications 
and a low risk of disseminating neoplastic cells when 
compared to the percutaneous approach. Cytological 
evaluation may have some disadvantages such as a limited 
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amount of material to make a diagnoses especially when 
differentiation between different tumor types is requested. 
Authors reported that EUS-FNA may be inconclusive 
or doubtful in up to 20% cases [8–13]. Explanations 
could be: (a) an inexperienced endosonographer, (b) 
small tumors in which it is often difficult to perform a 
biopsy and cytopathology performances are lower, (c) the 
absence of a cytopathologist to make on site sampling 
evaluation, (d) the presence of blood in the sample, (e) the 
diagnosis may be difficult in cases of well-differentiated 
adenocarcinoma and reactive atypia, (f) gastric and 
duodenum cell contamination. Today there are technical 
improvements, like new generations of needles and 
ultrasound machines, immunodetection and molecular 
biology which offer the possibility of diagnostic accuracy. 
One of the most important effects of teamwork is to 
facilitate a rapid diagnosis for the patient. In this case, 
the synergy between the cytopathologist and experienced 
ultrasonographer, demonstrates that it is possible to 
increase the accuracy of diagnosis. In our experience, the 
advantage of the rapid on-site evaluation (ROSE) during 
pancreatic EUS-FNA has been the following:  
(a)  real time confirmation of neoplastic cell 
specimens 
(b)  adequacy of the sample material for the purpose 
of molecular or immunocytochemistry analysis
(c)  contribution to the preoperative staging in the 
case of multifocal/multicentric tumors, lymph 
node involvment or distant metastasis
(d)  interdisciplinarity, evaluation and integration 
between clinical, radiological, laboratory and 
pathological data
(e)  contribution to the trainees for a faster learning 
curve
(f)  contribution to evolution of interventional 
maneuvers, for example the choice of trajectory, 
type and degrees of suction in the mass
In a previous study, we observed that one important 
factor impacting on transbronchial needle aspiration 
(TBNA) sensitivity, during fiberoptic bronchoscopy 
or mediastinoscopy, is the rapid on-site cytological 
examination (ROSE) [14]. The combination of EUS-
FNA and ROSE not only increases the percentage of 
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positive diagnoses, but also allows a significant reduction 
in expenses and time. This is an important factor 
because hospital managers have to respond not only 
for the efficacy, but also for the cost of their work. The 
technological progress has provided a great number of 
increasingly sophisticated and expensive tools. The task 
of the modern physician is to use equipment suitable 
for the patient’s needs, based on a careful evaluation of 
costs, benefits and risk-benefit ratio. Our experience with 
on-site cytology evaluation and EUS-FNA in pancreatic 
cancer, shows there are some weak points: a limitation 
of the available resources of personnel, and an increase 
in the waiting-time in cases that are difficult to diagnose. 
To achieve adequate performance, EUS-FNA must 
be carried out in highly-experienced centers, with the 
appropriate equipment and possibly with the aid of an 
on-site cytopathologist. However, on-site cytopathology 
interpretation may not be available in many centers.
Chang et al. reported that in the presence of an on-
site cytopathology assistant, during EUS-FNA, adequate 
specimens were obtained in 100% patients. On the 
contrary, the same study observed that absence of an 
on-site cytologist resulted in 29% of patients requiring a 
second procedure to obtain an adequate specimen [15]. 
Erickson et al observed, that when a cytopathologist was 
not on-site, in addition to prolonging procedure time 
and potentially increasing the procedural risk using 
multiple needle passes, the diagnostic yield of EUS-FNA 
dropped by 10–15% [16]. Tournoy et al. demonstrated 
that EUS-FNA with on-site cytopathology in mediastinal 
lymphadenopathy interpretation reported a diagnostic 
accuracy of 92% [17]. Bruno et al. observed that without 
and with on-site cytological examination, the application 
of TBNA in mediastinal lymphadenopathies determined 
a sensitivity of 65% and 80%, respectively. The same 
authors conclude that ROSE significantly improved the 
sensitivity of TBNA because the bronchoscopist can 
change the needle insertion point [14]. In our experience 
using EUS-FNA with ROSE in pancreatic suspected 
masses, it was possible to obtain a definitive diagnosis or 
an indication to continue with additional samples. Overall 
sensitivity, specificity, positive predictive value (PPV), 
negative predictive value (NPV) and diagnostic accuracy 
of cytology samples from EUS-FNA were 80.8%, 100%, 
100%, 72.2% and 87.2%, respectively (data not shown). 
The sensitivity and accuracy of combined histology and 
cytology was higher than histology or cytology alone. 
Histologic analysis revealed malignant cells that were not 
diagnosed by cytology, especially when there were excess 
of blood clots. In these cases, the blood material was fixed 
in formalin directly. 
The literature reports the risk of a false negative 
cytology during EUS-FNA in patients with chronic 
pancreatitis [18, 19], although this is not the only cause. 
Cell contamination during needle passages and the 
presence of excess blood covering the slide during on-
site evaluation, represent other possible causes of false 
negative. The former, depends on the cytopathologist’s 
experience. During the passages, the needle can sample 
single or groups of cells from stomach or duodenum, 
which are sometimes in layers, and it is difficult to 
distinguish them from the pancreatic tissues. The second 
problem can be excessive blood on the slide which covers 
the cells. The amount of blood may depend on the type of 
needle used. In this case, to prevent blood coagulation, 
the speed with which the material from the needle is 
smeared on the slide is very important. Differential 
diagnosis can be difficult because cells remain trapped 
in the fibrin. Even in experienced hands, these events 
may be encountered during EUS-FNA. Standardized 
terminology and nomenclature for pancreatic cytology 
provides guidance for the diagnosis of pancreatic lesions. 
Correlation between morphology, biological features and 
management recommendations is crucial in the presence 
of pancreatic massess and cysts. About that, an useful 
terminology scheme has been recently proposed [20]. 
This scheme allows the pathologist to classify lesions 
with a low grade of differentiation and slight atypias 
as compared to ductal pancreatic lesions frequently 
associated with marked cytological alterations. Following 
ROSE, there can be cases of specimens classified as 
inconclusive, indeterminate, or negative. For these cases, 
ancillary procedures including immunocytochemistry, 
fluorescence in situ hybridization, genetic analysis for 
neoplasia-specific mutations, and sequential mutational 
analysis are potentially useful in cytological interpretation. 
In conclusion, EUS-FNA offers great possibilities 
for future technological development like  increasingly 
defined imaging and more flexible needles to take 
samples from areas difficult to access. The ROSE is 
a method that, in its technical simplicity, has many 
advantages in terms of adequacy of cell material and 
preoperative cytologic diagnosis. In some cases ,with very 
few cells it is possible to carry out a number of diagnostic 
procedures for an accurate diagnosis. However, the 
pathologist must have experience in this specific field 
and work within a team where it is possible to have 
clinical and imaging information about the patient. After 
a careful morphological assessment, if the cytology alone 
is not conclusive, it may be better to apply ancillary tests, 
especially if biopsy material is not available and the 
cytological material is the only choice for diagnosis and 
therapy decision making. 
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